Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardioprotective Effect of rhBNP (Neucardin) in Emergency PCI for Acute Myocardial Infarction
ChiCTR2600118016Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of nesiritide in myocardial infarction (MI), heart failure (HF) and chronic kidney disease (CKD) (2 arms), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: NT pro-BNP. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
nesiritide
03
Conditions
myocardial infarction (MI)heart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2600118016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118016.